Search

everythinglearnresearchcommunity

for

Search:↓

The study presents the development of the TLMG hydrogel, a biointerface platform that forms in situ and adheres robustly to irregular skin wounds, offering enhanced mechanical properties and real-time signal monitoring for advanced wound management. By integrating tea polyphenols/lignin microspheres, the hydrogel combines bioelectronic and bioactive interfaces, achieving strong adhesion (200 kPa), high ionic conductivity (0.27 mS cm–1), and mechanical stability. Tested in complex animal models and human trials, the TLMG platform demonstrated intelligent wound management, dynamic signal monitoring, and improved wound healing through immunomodulatory mechanisms, highlighting its potential for wearable healthcare systems.

The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.